Epidermal Growth Factor-Like Repeats and Discoidin I-Like Domains 3 is a Novel Regulator of Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma: In Silico Analysis

Basit Öğe Kaydı
dc.authoridIlikci Sagkan, Rahsan/0000-0003-3844-6158
dc.contributor.authorSagkan, Rahsan Ilikci
dc.contributor.authorBali, Dilara Fatma Akin
dc.date.accessioned2024-11-07T13:32:03Z
dc.date.available2024-11-07T13:32:03Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractObjective: Epithelial-mesenchymal transition (EMT) contributes to cancer metastasis and recurrence, which are major obstacles in changing the course of cancer. However, studies on the mutational and gene expression profiles of epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3) that reveal the relationship between clear cell renal cell carcinoma (ccRCC) and EMT markers are limited. The aim of our study was to reveal the correlation between tumor and EMT markers (E-cadherin and vimentin) and EDIL3 expression. Additionally, we evaluated target gene expression levels and mutational profiles in kidney cancer tissue and normal tissue. Materials and Methods: We investigated the mutational profile and mRNA expression of EDIL3 and compared them with that of VIM and CDH1 in 523 patients with ccRCC using validated bioinformatics analysis. Additionally, Polymorphism Phenotyping v2 (PolyPhen-2), Screening for NonAcceptable Polymorphisms (SNAP) were used to predict and confirm the pathogenicity of the mutations detected. Studies were performed in silico using bioinformatics tools. Results: EDIL3 and VIM expression was statistically significantly higher in the healthy group and exhibited a positive correlation in patients with ccRCC. Patients with elevated VIM and CDH1 expression and low EDIL3 expression had prolonged survival time. In addition, 7 mutations were detected in the evaluated genes, 6 of which had potential pathogenic features. Conclusion: Our study provides insights for further experimental studies. EDIL3 can be used as a diagnostic or prognostic indicator of cancer development to help cure renal clear cell cancer.
dc.identifier.doi10.14744/etd.2020.47827
dc.identifier.endpage129
dc.identifier.issn2149-2247
dc.identifier.issn2149-2549
dc.identifier.issue2
dc.identifier.startpage122
dc.identifier.trdizinid487854
dc.identifier.urihttps://doi.org/10.14744/etd.2020.47827
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/487854
dc.identifier.urihttps://hdl.handle.net/11480/15200
dc.identifier.volume43
dc.identifier.wosWOS:000626292700004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherErciyes Univ Sch Medicine
dc.relation.ispartofErciyes Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectEpidermal growth factor-like repeats and discoidin I-like domains 3
dc.subjectepithelial-mesenchymal transition
dc.subjectclear cell renal cell carcinoma
dc.subjectmutation
dc.subjectgene expression
dc.titleEpidermal Growth Factor-Like Repeats and Discoidin I-Like Domains 3 is a Novel Regulator of Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma: In Silico Analysis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu